Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > REGULATORY
REGULATORY
- Japan Approves Label Expansion for Enhertu, TS-1, and More
November 25, 2022
- Upper House Health Committee OKs Bill to Amend Infectious Disease Act
November 25, 2022
- LDP Pharma Study Group Calls for Careful Discussions on Off-Year Plan: Proposal
November 25, 2022
- LDP Lawmakers’ League Boots Up for Medical Adhesive Patches
November 24, 2022
- LDP League Urges MEXT to Provide Accurate Info on HPV Vaccines at Medical Schools
November 24, 2022
- MOF Panel Proposal Expected to Spell Out Full Annual Price Revision
November 24, 2022
- Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
November 24, 2022
- Defense Buildup Won’t Impact Degree of Cuts in Social Security Costs: MHLW Official
November 22, 2022
- Bill to Amend Intractable Disease Law Passes Lower House
November 22, 2022
- Enough Antipyretic Analgesic Agents Secured for Twindemic, MHLW Says
November 21, 2022
- LDP Tax Council to Compile FY2023 Reform Proposal by Mid-December
November 21, 2022
- Govt to Designate 4 β-Lactam Antibiotics as Key Resources by Year-End
November 18, 2022
- Chuikyo Reps Tussle over Product Coverage Threshold for Off-Year Price Revision
November 17, 2022
- Evrenzo to Add Hypothyroidism Risk in Label Revision
November 17, 2022
- MHLW Unveils Overview of Genome Analysis Project Organ for FY2025 Launch
November 17, 2022
- MHLW to Run Health Survey for COVID-19 Vaccination in Children
November 16, 2022
- LDP Legislators Push for “No Off-Year Price Revision”: Health Committee
November 16, 2022
- LDP Lawmakers Throw Support Behind Pharma on Off-Year Plan
November 15, 2022
- Japan’s 4th Avastin Biosimilar, Kit Products Get Listing; No Follow-On for New API in FY2022
November 15, 2022
- LEO Pharma’s Atopic Dermatitis Med Tralokinumab Up for MHLW Panel Review on November 28
November 15, 2022
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…